Efficacy of Inpatient Psychotherapy for Major Depressive Disorder: a Meta-analysis of Controlled Trials
Overview
Authors
Affiliations
Objective: This meta-analysis investigates the efficacy of inpatient psychotherapy in major depressive disorders compared to control conditions.
Methods: In total, 14 studies were entered into the meta-analysis with a total of 1.080 patients. Primary outcome was the standardized mean differences in self-rated depression outcomes. A priori planned subgroup analyses included the influence of different control conditions: (a) no psychiatric inpatient treatment (e.g., waitlist control), (b) treatment as usual (TAU; e.g., non-manualized clinical management), (c) TAU determined by study design (manualized/'placebo' control condition), as well as number of sessions and influence of self- vs. clinician ratings.
Results: The meta-analysis of 19 available comparisons resulted in a moderate pooled effect size showing a small and statistically significant benefit of the psychotherapeutic intervention over control conditions (g = 0.24, P < 0.001, I = 0%). This corresponds to a number needed to treat of 7.4. The effects of the interventions were stable over 12-month follow-up (g = 0.21, P < 0.01, I = 30%). Comparisons with waitlist or non-standardized control treatments tended to be associated with larger effect sizes than standardized control treatments.
Conclusions: Despite some limitations (small number of studies), this meta-analysis provides evidence for a small but sustained effect of inpatient psychotherapy in patients with major depressive disorders.
Changes in patient-reported outcomes during admission to a South African psychiatric facility.
Motshudi L, Hann C, Kloppers M, Luhandjula T, Phalatse T, Pretorius D S Afr J Psychiatr. 2024; 30:2258.
PMID: 39363942 PMC: 11447592. DOI: 10.4102/sajpsychiatry.v30i0.2258.
Doering S, Herpertz S, Pape M, Hofmann T, Rose M, Imbierowicz K Front Psychiatry. 2023; 14:1155582.
PMID: 37608994 PMC: 10440687. DOI: 10.3389/fpsyt.2023.1155582.
[Inpatient psychotherapy of depressive disorders: options and challenges].
Brakemeier E, Guhn A, Stapel S, Reinhard M, Padberg F Nervenarzt. 2023; 94(3):213-224.
PMID: 36853327 DOI: 10.1007/s00115-023-01448-w.
Herzog P, Lauff S, Rief W, Brakemeier E Brain Behav. 2019; 9(12):e01447.
PMID: 31647202 PMC: 6908878. DOI: 10.1002/brb3.1447.